Sun Pharmaceutical Industries Limited — Updates, 21-07-2025: Press Release

Sun Pharma's ILUMYA drug met primary endpoints in two pivotal Phase 3 studies (INSPIRE-1 & INSPIRE-2) for active psoriatic arthritis. The trials demonstrated statistically significant improvements in ACR20 response rates at Week 24 compared to placebo. Importantly, the safety data aligns with ILUMYA's known profile, with no new safety signals observed. These positive results pave the way for a potential regulatory submission in the US, indicating a significant step towards expanding ILUMYA's market beyond plaque psoriasis and addressing a critical patient need.